ADAPTIMMUNE THERAPEUTICS PLC - AMERICAN DEPOSITARY

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

11 5 2021 08:00:02 提供 Nasdaq GlobeNewswire

Adaptimmune Reports First Quarter Financial Results and Business Update

06 5 2021 07:30:01 提供 Nasdaq GlobeNewswire

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

27 4 2021 16:30:00 提供 Nasdaq GlobeNewswire

Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

22 4 2021 08:00:02 提供 Nasdaq GlobeNewswire

Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

25 2 2021 07:30:00 提供 Nasdaq GlobeNewswire

Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021

11 2 2021 08:00:02 提供 Nasdaq GlobeNewswire